Patents by Inventor Richard Begent

Richard Begent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies against tumor surface antigens
    Publication number: 20080003646
    Abstract: The present invention relates to improved antibodies against tumor surface antigens and their use in the treatment of tumors. Of particular interest are highly stable, humanized, high affinity antibodies against carcinoembryonic antigen (CEA), especially the antibody we have termed sm3E, which is derived from the scFv antibody MFE-23. Such antibodies have the potential for improved therapeutic efficacy.
    Type: Application
    Filed: May 29, 2007
    Publication date: January 3, 2008
    Applicants: Cancer Research Technology Limited, Massachusetts Institute of Technology
    Inventors: Richard Begent, Kerry Chester, Christilyn Graff, K. Wittrup
  • Antibodies against tumor surface antigens
    Publication number: 20050147614
    Abstract: The present invention relates to improved antibodies against tumor surface antigens and their use in the treatment of tumors. Of particular interest are highly stable, humanized, high affinity antibodies against carcinoembryonic antigen (CEA), especially the antibody we have termed sm3E, which is derived from the scFv antibody MFE-23. Such antibodies have the potential for improved therapeutic efficacy.
    Type: Application
    Filed: July 1, 2003
    Publication date: July 7, 2005
    Inventors: Richard Begent, Kerry Chester, Christilyn Graff, K. Wittrup
  • Modifided carboxypeptidase enzymes and their use
    Publication number: 20050059133
    Abstract: The invention relates to improvements relating to cancer therapy based on the identification of a number of regions of CPG2 which contain epitopes which appear to be involved in the production of a host immune response and which may be modified to alter the immunogenicity in patients. Production of fusions of CPG2 with an antibody, where the CPG2 protein has been tagged provides a CPG2 protein which has reduced immunogenicity. By using partially glycosylated enzyme obtainable by P. pastoris expression, the efficacy of antibody-CPG2 fusions is enhanced.
    Type: Application
    Filed: October 2, 2003
    Publication date: March 17, 2005
    Applicant: Cancer Research Technology Limited
    Inventors: Richard Begent, Kerry Chester, Nigel Minton, Anthony Rees, Surinder Sharma, Daniel Spencer